SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (2230)3/24/2005 1:35:02 PM
From: scaram(o)uche  Read Replies (3) | Respond to of 12215
 
Ian:

Mixed thoughts..... I've long been interested in toll receptor agonists, deriving from an age-old observation re. "innate" IgM responses. I believe that they'll eventually be useful for allergy. But, for the vast majority of human cancers??..... pissing into outer space, IMO.

TLR9 agonists are potent "adjuvants" which enhance the "innate" immune response. In addition, they can enhance the "adaptive" immune response to a variety of foreign antigens.

Pfizer's management team has been under a little too much stress??

Rick



To: Ian@SI who wrote (2230)8/20/2005 3:25:01 AM
From: tuck  Read Replies (3) | Respond to of 12215
 
Signals has a recent article on the subject of Toll-like receptors, and identifies other players, as well as offering a primer on the science:

signalsmag.com

Note that Hybridon's partnered program goes after asthma and allergy, which Rick alluded to as more likely diseases to target by this path. Unfortunately, they currently have their cancer program to themselves.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News